# Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy

> **NCT01909388** · PHASE2 · UNKNOWN · sponsor: **Alfonso Gomez-Iturriaga** · enrollment: 15 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** MRI-TRUS fusion guided real time HDR

## Key facts

- **NCT ID:** NCT01909388
- **Lead sponsor:** Alfonso Gomez-Iturriaga
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-06
- **Primary completion:** 2014-05
- **Final completion:** 2016-07
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2013-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01909388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01909388, "Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01909388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*